Common Stock, par value $0.001 per share
- Symbol
- APUS
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Apimeds Pharmaceuticals US, Inc.
APUSNYSE_AMERICANEQUITYCurrent
Other Events
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ───────────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release issued by MindWave Innovations Inc. dated September 24, 2026 (AQUAEChain). 99.2 Press Release issued by MindWave Innovations Inc. dated September 29, 2026 (FlashChain).…
Press release in this filing
MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure →Company context
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Current securities
Recent company filings
- Other EventsOct 13, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 1, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearSep 23, 2026
- Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
- Entry into a Material Definitive AgreementAug 21, 2026
Registered securities in this filing
Apimeds Pharmaceuticals US, Inc. · 8-K · Filed 2026-09-29
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
No.
─────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release issued by MindWave Innovations Inc. dated September 24, 2026 (AQUAEChain).
99.2 Press Release issued by MindWave Innovations Inc. dated September 29, 2026 (FlashChain).
104 Cover
Page Interactive Data File (embedded within the inline XBRL document)
Filed exhibits (2)
Exhibit 99.1 MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure Agreement strengthens MindWave’s position as a technology provider for ecosystem finance and environmental markets MATAWAN, New Jersey - September 24, 2026 - MindWave Innovations Inc. (“MindWave”), a subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has entered into a 12-month strategic technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. (“AQUAE”) to deploy MindWave’s MindChain infrastructure as the foundational technology powering AQUAEChain. Under the agreement, MindWave will deploy MindChain as the core blockchain infrastructure powering AQUAEChain, enabling the secure issuance, traceable lifecycle management, verification, transaction, and retirement of insured ALCI Credits. In addition to contracted software development and technology service fees, the agreement references an allocation to MindWave equal to 20% of the total ALCI Credits issued and outstanding on the AQUAEChain network. The allocation would be calculated at the end of each quarter using the MindChain issuance ledger. The engagement represents a significant achi…
Open exhibit ↗Exhibit 99.2 MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media The 12-month agreement covers a dedicated MindChain subnet for authenticating digital match tickets, sports memorabilia and media assets MATAWAN, New Jersey, Sept. 29, 2026 - MindWave Innovations Inc. (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings, Inc. (Ticker: FLZH) (“FLZH”) to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. Under the agreement, MindWave will deploy a dedicated subnet for FlashChain on MindChain’s Layer-2 infrastructure, operate the validator nodes that run it, and issue FLZH the cryptographic keys and secure connections it needs to access the network. FLZH will own the FlashChain network, its brand and its Digital Asset and Ticketing Ledger, which will record authenticated digital match tickets, digital sports memorabilia and related media-asset t…
Open exhibit ↗